Emergent BioSolutions

EBSPhase 3

Emergent BioSolutions is a publicly traded biopharmaceutical company specializing in medical countermeasures against public health threats, including chemical, biological, radiological, and nuclear (CBRN) agents, as well as emerging infectious diseases. The company operates through a fully integrated model encompassing development, manufacturing, and commercialization. Its portfolio includes FDA-approved products for anthrax, smallpox, botulism, and opioid overdose, positioning it as a critical partner to governments worldwide. Emergent's strategic focus is on preparedness and rapid response capabilities for health security emergencies.

Market Cap

$424.0M

Employees

1,500-2,000

Focus

BiologicsVaccines

EBS · Stock Price

USD 8.1936.01 (-81.47%)

Historical price data

AI Company Overview

Technology Platform

Fully integrated development, manufacturing, and commercialization capabilities specialized in medical countermeasures for public health threats, utilizing regulatory pathways like the FDA Animal Rule.

Pipeline Snapshot

48 drugs in pipeline, 7 in Phase 3

Drug	Indication	Stage
Vaccination with ACAM2000	Smallpox Vaccine Adverse Reaction	Approved
Blood sample collection	Botulism	Approved
AVA + Raxibacumab + Diphenhydramine	Infections, Bacterial	Approved
Sample Collection	Infections, Bacterial	Approved
AV7909 + BioThrax	Anthrax	Phase 3

Opportunities

Growth opportunities include the potential FDA approval and procurement of NuThrax, successful Phase 3 data and licensing for the chikungunya vaccine, expansion of OTC NARCAN sales, and leveraging its CDMO capabilities for pandemic preparedness and emerging infectious disease partnerships.

International expansion of its product portfolio and services also presents an opportunity.

Risk Factors

Key risks include high dependence on U.S.

government funding and contracts, ongoing FDA compliance and manufacturing quality issues at key sites, a concentrated pipeline with high stakes on few late-stage assets, significant debt burden, and intense competition in both the biodefense and CDMO sectors.

Competitive Landscape

Main competitors include Bavarian Nordic in vaccines, Ology Bioservices in biodefense contracts, and large CDMOs like Lonza and Catalent. Emergent differentiates through its deep government relationships, fully integrated model from development to stockpiling, and a portfolio of approved products that are cornerstone assets in national preparedness plans.

Publications

Patents

Pipeline

Company Info

TypeTherapeutics

Founded1998

Employees1,500-2,000

LocationGaithersburg, United States

StagePhase 3

RevenueRevenue Generating

Trading

TickerEBS

ExchangeNYSE

Contact

emergentbiosolutions.com

Therapeutic Areas

BiodefenseInfectious DiseaseOverdose ReversalPublic Health

Sectors

Biologics / Biosimilars

Partners

U.S. Department of Health and Human Services (HHS)Biomedical Advanced Research and Development Authority (BARDA)U.S. Department of Defense (DoD)Centers for Disease Control and Prevention (CDC)Valneva SE (CHIKV vaccine acquisition)Adapt Pharma (NARCAN acquisition)

SIMILAR COMPANIES